Publications by authors named "R LASSER"

Article Synopsis
  • Zuranolone is a new treatment for postpartum depression approved for a 14-day course and is being studied for how it transfers into breast milk.
  • In this study, lactating participants took a daily dose of 30 mg zuranolone, and the transfer was measured, revealing a relative infant dose (RID) of 0.357% after 5 days.
  • The findings suggest that the transfer of zuranolone into breast milk is low and stays well below the 10% threshold that is considered safe for breastfeeding.
View Article and Find Full Text PDF
Article Synopsis
  • Zuranolone is a new oral treatment for postpartum depression and is being studied for major depressive disorder, acting as a modulator of GABA receptors in the brain.
  • The ongoing SHORELINE Study aims to assess the long-term safety and effectiveness of zuranolone in adults with major depressive disorder, with patients undergoing treatment for up to 1 year.
  • Preliminary results show that a significant percentage of patients experienced mild to moderate side effects, but there were notable improvements in depression scores after initial and repeat treatments.
View Article and Find Full Text PDF
Article Synopsis
  • - Major depressive disorder (MDD) can significantly impact a person's ability to function and traditional antidepressant treatments take weeks to show effects; zuranolone is a new oral treatment that's been approved for postpartum depression and is being studied for MDD.
  • - The CORAL Study tested the effectiveness of zuranolone (50 mg) when combined with standard antidepressant therapy against a placebo in 425 adults with MDD, focusing on improvements in depression symptoms within the first three days.
  • - Results showed that patients taking zuranolone experienced a greater reduction in depression scores by Day 3 compared to those on placebo, with mild to moderate side effects being the most common, such as drowsiness and headaches.
View Article and Find Full Text PDF
Article Synopsis
  • Postpartum depression (PPD) is a common issue affecting new mothers, and this study explored the effectiveness and safety of zuranolone as a treatment option over a 14-day period.
  • In a phase 3 trial with 196 participants, those taking zuranolone showed significant improvements in depression scores compared to those on a placebo, with benefits noted as early as day 3.
  • The treatment was well tolerated, with some side effects like somnolence and dizziness, but no serious risks such as loss of consciousness or increased suicidal thoughts were reported.
View Article and Find Full Text PDF
Article Synopsis
  • * Patients in the zuranolone group experienced notable symptom relief as early as day 3, and this improvement was sustained through day 15 and beyond, with a statistically significant change from baseline scores.
  • * The treatment was generally well tolerated, with similar rates of serious adverse events in both the zuranolone and placebo groups, suggesting its potential as a viable option for treating major depressive disorder.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionhhbavo28jb356d5qhgknvkg669ct7rvr): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once